Endometrial cancer metastatic

8 trials 2 recruiting MedDRA PT
8 Registered trials
2 Recruiting
6 Unique sponsors
6 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Kinase inhibitor 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 3 Phase II: 2 Phase I: 2 Phase I (Other): 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

3 trials
  • AstraZeneca AB Commercial
    AZD8205
    2024-518777-34-00 15 countries 2026 n=187
    Recruiting
  • Genmab A/S Commercial
    RINATABART SESUTECAN
    2024-519818-31-01 11 countries n=226
    Pending
  • Karyopharm Therapeutics Inc. Commercial
    IMP not specified
    2024-513167-68-00 6 countries 2017 n=70
    Ended

Phase II

2 trials
  • Incyte Corp. Commercial
    HUMAN IGG1K MONOCLONAL ANTIBODY AGAINST TIM-3; PEMIGATINIB; RETIFANLIMAB; TUPARSTOBART
    2022-502600-79-00 4 countries 2021 n=88
    Ended
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2023-509619-10-00 1 country 2024 n=60
    Ended

Phase I

2 trials
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2024-516660-28-00 1 country n=15
    Not authorised
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2024-516660-28-01 1 country 2026 n=15
    Recruiting

Phase I (Other)

1 trial
  • Exelixis Inc. Commercial
    IMP not specified
    2024-516477-73-00 2 countries 2018 n=320
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Vall D Hebron Institute Of Oncology Academic 3 Phase I, Phase II 1
Exelixis Inc. Commercial 1 Phase I (Other) 0
Incyte Corp. Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase III 1
Genmab A/S Commercial 1 Phase III 0
Karyopharm Therapeutics Inc. Commercial 1 Phase III 0
New trials by year
2021
1
2024
1
2026
2
← All indication landscapes